It's a crying shame our RSV candidates since 2009 have had...

It's a crying shame our RSV candidates since 2009 have had plenty of stop starts. Back then we pretty much had the whole field to ourselves. I'm hoping all the tweaking and lessons learnt from previous two candidates means what eventually gets to the clinic is more durable and less susceptible to failure viz our competitors. Surely we would have amassed a lot of corporate knowledge in this area.

As for Vap. This is a few years into the future but I wouldnt be surprised if government may even fund it for broader indications e.g. Polio virus antiviral etc. I haven't given up on some bio defense kinda indication.